MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This study wants to find out how much of a new medicine called elranatamab should be given to people with a type of cancer called multiple myeloma, and if it helps them feel better. The medicine will be given along with other cancer treatments.
This study wants to find out how much of a new medicine called elranatamab should be given to people with a type of cancer called multiple myeloma, and if it helps them feel better. The medicine will be given along with other cancer treatments.
*Third Opinion AI Generated Synopsis
Trial Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: